Figure 3 | Scientific Reports

Figure 3

From: Impact of switching between reference biologics and biosimilars of tumour necrosis factor inhibitors for rheumatoid arthritis: a systematic review and network meta-analysis

Figure 3

Possible treatment networks for a) ACR20 and b) HAQ-DI.The graph in Fig. 3 (panel A) comprises four nodes representing two non-switching arms (Ref-Ref, Bios-Bios) and two switching arms (Ref-Bios and Bios-Ref), and six edges (arrows). Figure 3 (panel B) comprises three nodes representing two non-switching arms (Ref-Ref, Bios-Bios) and one switching (Ref-Bios), and three edges (arrows). The size of nodes is proportional to the number of patients analyzed for interventions. The thickness of lines is proportional to the number of studies contributing to the direct comparison. ACR20: the American College of Rheumatology 20% response criteria; HAQ-DI: the Health Assessment Questionnaire—Disability Index (HAQ-DI). Ref -Ref: patients taking reference biologics drugs continued the treatment (non-switching group); Bios-Bios: patients taking biosimilars continued the treatment (non-switching group); Ref-Bios: patients taking reference biologics drugs switched to biosimilars (switching group); Bios-Ref: patients taking biosimilars switched to reference biologics drugs (switching group).

Back to article page